Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of a Prophylactic COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults (ProVIVA-SA-1)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Oct 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs COVID-2019 vaccine-ImmunityBio (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics
Acronyms ProVIVA-SA-1
Sponsors ImmunityBio

Most Recent Events

26 Sep 2023 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.
26 Sep 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Sep 2023.
14 Sep 2022 Planned End Date changed from 1 Apr 2022 to 1 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight